Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Multihance clinical pharmacology: biodistribution and MR enhancement of the liver.

× No keyword cloud information.

24 in total

1. Malignant focal liver lesions at contrast-enhanced ultrasonography and magnetic resonance with hepatospecific contrast agent.

Authors: M D'Onofrio; S Crosara; R De Robertis; S Canestrini; V Cantisani; G Morana; R Pozzi Mucelli
Journal: Ultrasound Date: 2013-12-13

2. Detection of malignant primary hepatic neoplasms with gadobenate dimeglumine (Gd-BOPTA) enhanced T1-weighted hepatocyte phase MR imaging: results of off-site blinded review in a phase-II multicenter trial.

Authors: C S Peña; S Saini; R L Baron; B A Hamm; G Morana; R Caudana; A Giovagnoni; A Villa; A Carriero; D Mathieu; M W Bourne; M A Kirchin; G Pirovano; A Spinazzi
Journal: Korean J Radiol Date: 2001 Oct-Dec Impact factor: 3.500

Review 3. Clinical applications of gadobenate dimeglumine-enhanced magnetic resonance cholangiography: an expanded pictorial review.

Authors: Baris Turkbey; Erhan Akpinar; Omur Balli; Bulent Tirnaksiz; Deniz Akata; Okan Akhan; Musturay Karcaaltincaba
Journal: Jpn J Radiol Date: 2011-01-26 Impact factor: 2.374

4. Gadoxetic acid (Gd-EOB-DTPA)-enhanced MRI versus gadobenate dimeglumine (Gd-BOPTA)-enhanced MRI for preoperatively detecting hepatocellular carcinoma: an initial experience.

Authors: Yulri Park; Seong Hyun Kim; Seung Hoon Kim; Yong Hwan Jeon; Jongmee Lee; Min Ju Kim; Dongil Choi; Won Jae Lee; Heejung Kim; Ji Hyun Koo; Hyo Keun Lim
Journal: Korean J Radiol Date: 2010-06-21 Impact factor: 3.500

Review 5. Biodistribution of gadolinium-based contrast agents, including gadolinium deposition.

Authors: Silvio Aime; Peter Caravan
Journal: J Magn Reson Imaging Date: 2009-12 Impact factor: 4.813

Review 6. Biochemical safety profiles of gadolinium-based extracellular contrast agents and nephrogenic systemic fibrosis.

Authors: Hale Ersoy; Frank J Rybicki
Journal: J Magn Reson Imaging Date: 2007-11 Impact factor: 4.813

7. Preclinical investigation to compare different gadolinium-based contrast agents regarding their propensity to release gadolinium in vivo and to trigger nephrogenic systemic fibrosis-like lesions.

Authors: Martin A Sieber; Philipp Lengsfeld; Thomas Frenzel; Sven Golfier; Heribert Schmitt-Willich; Fred Siegmund; Jakob Walter; Hanns-Joachim Weinmann; Hubertus Pietsch
Journal: Eur Radiol Date: 2008-06-11 Impact factor: 5.315

8. Gadobenate dimeglumine-enhanced liver MR imaging: value of dynamic and delayed imaging for the characterization and detection of focal liver lesions.

Authors: Young Kon Kim; Jeong Min Lee; Chong Soo Kim
Journal: Eur Radiol Date: 2003-11-05 Impact factor: 5.315

Review 9. Hypointense hepatic lesions depicted on gadobenate dimeglumine-enhanced three-hour delayed hepatobiliary-phase MR imaging: differentiation between benignancy and malignancy.

Authors: Hye Sun Hwang; Seong Hyun Kim; Tae Yeon Jeon; Dongil Choi; Won Jae Lee; Hyo K Lim
Journal: Korean J Radiol Date: 2009-04-22 Impact factor: 3.500

Review 10. Contrast agents for hepatic MRI.

Authors: Giovanni Morana; Elisabetta Salviato; Alessandro Guarise
Journal: Cancer Imaging Date: 2007-10-01 Impact factor: 3.909